Related references
Note: Only part of the references are listed.Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
C. Krakstad et al.
BRITISH JOURNAL OF CANCER (2012)
KrasG12D-Induced IKK2/β/NF-κB Activation by IL-1α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma
Jianhua Ling et al.
CANCER CELL (2012)
Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1
Jean McBryan et al.
CANCER RESEARCH (2012)
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation
Sandra Sernbo et al.
BMC CANCER (2011)
Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin
S. Rachagani et al.
BRITISH JOURNAL OF CANCER (2011)
Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer
Jone Trovik et al.
CLINICAL CANCER RESEARCH (2011)
Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
Hidefumi Sasaki et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma
Patrick L. Wagner et al.
LUNG CANCER (2011)
Emerging therapeutic targets in endometrial cancer
Konstantin J. Dedes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer
J-S Zhang et al.
ONCOGENE (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors
Virna Cepero et al.
CANCER RESEARCH (2010)
Hypoxia Activates the K-Ras Proto-Oncogene to Stimulate Angiogenesis and Inhibit Apoptosis in Colon Cancer Cells
Min Zeng et al.
PLOS ONE (2010)
In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Non-Small Cell Lung Carcinoma
Patrick L. Wagner et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma
Bozena Dobrzycka et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2009)
Endometrioid uterine cancer: Histopathological risk factors of local and distant recurrence
Toshio Fujimoto et al.
GYNECOLOGIC ONCOLOGY (2009)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
H. B. Salvesen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
GATA3 expression in estrogen receptor α-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival
Ingeborg B. Engelsen et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2008)
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCICIND-148
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Origin and prognostic value of circulating KRAS mutations in lung cancer patients
O. Gautschi et al.
CANCER LETTERS (2007)
Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas
Ingeborg B. Engelsen et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status
KI Pappa et al.
GYNECOLOGIC ONCOLOGY (2006)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Share Paper
